Jan 6, 2023
Damar Hamlin, obesity and semaglutide, Open Data and PCSK9 inhibitors, and TAVI vs SAVR trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I. Damar Hamlin
Five Thoughts on the Damar Hamlin Collapse
II. Semaglutide and Obesity in Adolescents
FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up
• Once-Weekly Semaglutide in Adolescents with Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2208601
III. Open Data and PCSK9 inhibitors
Evolocumab Added to Statins Cuts CV Events in FOURIER Trial
• Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
• PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction https://pubmed.ncbi.nlm.nih.gov/34252181/
• Bendary Tweet https://twitter.com/DrBendary/status/1609849852979986432?s=20&t=FDDhGIofS_HQ4jxf8aHwBA
IV. Open Data and TAVI vs SAVR Trials
Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799937
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
Questions or feedback, please contact email@example.com